Clinical and Translational Oncology

, Volume 21, Issue 3, pp 334–341 | Cite as

TIPE1 suppresses osteosarcoma tumor growth by regulating macrophage infiltration

  • P. Chen
  • J. Zhou
  • J. Li
  • Q. Zhang
  • Q. ZuoEmail author
Research Article



Osteosarcoma is the most common primary malignancy of the bone, and macrophages play a promotional role during osteosarcoma development and progression. TIPE1 is known to function as a tumor suppressor in diverse cancers by inducing cell arrest and apoptosis. However, the biological function of TIPE1 in osteosarcoma is still unclear.


The purpose of this study was to investigate the expression and function of TIPE1 in osteosarcoma.


In the present study, TIPE1 expression in osteosarcoma cancer cells was determined by qPCR and western blotting. A subcutaneous tumor model was established to investigate the potential anti-tumor activity of TIPE1 in osteosarcoma. Further, flow cytometry, western blotting, immunofluorescence staining, and ELISA were performed to clarify the underlying mechanism by which TIPE1 regulates growth of osteosarcoma.


Our results suggest that TIPE1 is downregulated in osteosarcoma cancer cells, and ectopic expression TIPE1 significantly inhibited osteosarcoma tumor growth in vivo. Furthermore, TIPE1 inhibits the infiltration of macrophages in osteosarcoma tumor by suppressing MCP-1 expression in osteosarcoma cells. Further in vivo study revealed that inhibition of MCP-1/CCR2 axis by Bindarit blocked the inhibitory effect of TIPE1 on osteosarcoma growth.


Collectively, our results demonstrate the anti-tumor role of TIPE1 in osteosarcoma and reveal a novel therapy target for osteosarcoma.


Osteosarcoma TIPE1 Macrophages MCP-1 



The present study was supported by Natural Science Foundation of Jiangsu Province (BK20161069).

Author contributions

PC and JCZ were involved in the acquisition of the data. JML and QZ were involved in the analysis and interpretation of the data. QZ was involved in the conception and design of the present study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. Scholar
  3. 3.
    Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer. 2003;98(11):2447–56. Scholar
  4. 4.
    Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 2009;27(4):557–65. Scholar
  5. 5.
    Rivera-Valentin RK, Zhu L, Hughes DP. Bone sarcomas in pediatrics: progress in our understanding of tumor biology and implications for therapy. Paediatr Drugs. 2015;17(4):257–71. Scholar
  6. 6.
    Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, et al. NCCN Guidelines Insights: bone Cancer, Version 2.2017. J Natl Compr Cancer Netw: JNCCN. 2017;15(2):155–67.CrossRefGoogle Scholar
  7. 7.
    Marx J. Cancer biology. All in the stroma: cancer’s Cosa Nostra. Science (New York, NY). 2008;320(5872):38–41. Scholar
  8. 8.
    Yuan Y, Jiang YC, Sun CK, Chen QM. Role of the tumor microenvironment in tumor progression and the clinical applications (review). Oncol Rep. 2016;35(5):2499–515. Scholar
  9. 9.
    Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, et al. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol. 2015;35:S199–223. Scholar
  10. 10.
    Rhee I. Diverse macrophages polarization in tumor microenvironment. Arch Pharmacal Res. 2016;39(11):1588–96. Scholar
  11. 11.
    Kim J, Bae JS. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediat Inflamm. 2016;2016:6058147. Scholar
  12. 12.
    Wu X, Ma Y, Cheng J, Li X, Zheng H, Jiang L, et al. TIPE1 function as a prognosis predictor and negative regulator of lung cancer. Oncotarget. 2017;8(45):78496–506. Scholar
  13. 13.
    Zhang Z, Liang X, Gao L, Ma H, Liu X, Pan Y, et al. TIPE1 induces apoptosis by negatively regulating Rac1 activation in hepatocellular carcinoma cells. Oncogene. 2015;34(20):2566–74. Scholar
  14. 14.
    Liu W, Chen Y, Xie H, Guo Y, Ren D, Li Y, et al. TIPE1 suppresses invasion and migration through down-regulating Wnt/beta-catenin pathway in gastric cancer. J Cell Mol Med. 2017. Scholar
  15. 15.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2–ΔΔCT method. Methods (San Diego, Calif). 2001;25(4):402–8. Scholar
  16. 16.
    Dai L, Cui X, Zhang X, Cheng L, Liu Y, Yang Y, et al. SARI inhibits angiogenesis and tumor growth of human colon cancer through directly targeting ceruloplasmin. Nat Commun. 2016;7:11996. Scholar
  17. 17.
    Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208–20. Scholar
  18. 18.
    Xiao Q, Zhang X, Wu Y, Yang Y. Inhibition of macrophage polarization prohibits growth of human osteosarcoma. Tumor Biol. 2014;35(8):7611–6. Scholar
  19. 19.
    Segaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, et al. Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer. 2015;137(1):73–85. Scholar
  20. 20.
    Kimura Y, Sumiyoshi M, Baba K. Antitumor and antimetastatic activity of synthetic hydroxystilbenes through inhibition of lymphangiogenesis and M2 macrophage differentiation of tumor-associated macrophages. Anticancer Res. 2016;36(1):137–48.Google Scholar
  21. 21.
    Han Q, Shi H, Liu F. CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. Int Immunopharmacol. 2016;34:101–6. Scholar
  22. 22.
    Wolfs IM, Donners MM, de Winther MP. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost. 2011;106(5):763–71. Scholar
  23. 23.
    Zou K, Wang Y, Hu Y, Zheng L, Xu W, Li G. Specific tumor-derived CCL2 mediated by pyruvate kinase M2 in colorectal cancer cells contributes to macrophage recruitment in tumor microenvironment. Tumor Biol. 2017;39(3):1010428317695962. Scholar
  24. 24.
    Hultgren EM, Patrick ME, Evans RL, Stoos CT, Egland KA. SUSD2 promotes tumor-associated macrophage recruitment by increasing levels of MCP-1 in breast cancer. PLoS One. 2017;12(5):e0177089. Scholar
  25. 25.
    Chen Q, Sun W, Liao Y, Zeng H, Shan L, Yin F, et al. Monocyte chemotactic protein-1 promotes the proliferation and invasion of osteosarcoma cells and upregulates the expression of AKT. Mol Med Rep. 2015;12(1):219–25. Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  1. 1.Department of OrthopedicsAffiliated Yancheng Hospital, School of Medicine, Southeast UniversityNanjingChina
  2. 2.Department of OrthopedicsThe First Affiliated Hospital of Nanjing Medical UniversityNanjingChina

Personalised recommendations